**MKP: Explaining the fluctuations of separate profit and consolidated profit in 2023 (audited)**

On April 16, 2024, Mekophar Chemical Pharmaceutical Joint Stock Company announced Official Dispatch No. 06/TKKT on explaining the fluctuations of profit of the Separate Financial Statements 2023 and the Consolidated Financial Statements 2023 compared to the same period last year, as follows:

The Financial Statements of the holding company in 2023:

Profit after tax in 2023 decreased by VND 16,557,121,651, decreased by 39.7% compared to the same period last year. The reason is that the total revenue decreased by VND 279,175,754,556, decreased by 23.8% and the general and administrative expenses increased by VND 23,475,545,725, equivalent to 22.5%.

Consolidated Financial Statements 2023

Profit after tax in 2023 decreased by VND 16,576,797,227, equivalent to 39.8% compared to the same period last year. The reason is that the total revenue decreased by VND 288,403,569,684, equivalent to 24.2%, while the general and administrative expenses increased by VND 21,566,701,027, equivalent to 16.6%.

On April 16, 2024, Mekophar Chemical Pharmaceutical Joint Stock Company announced Official Dispatch No. 07/TKKT on the delay in explaining the difference in profit after tax after the audit as follows:

On April 15, 2024, Mekophar Chemical Pharmaceutical Joint Stock Company (Mekophar Company) received Official Dispatch No. 885/SGDHN-QLNY dated April 10, 2024 on explaining the delay in explanation the Financial Statements after the audit.

Due to the lack of understanding of the content of the provisions in Clause 1, Article 7 of Circular No. 96/2020/TT-BTC dated November 16, 2020 of the Ministry of Finance, the Joint Stock Company is lacking in the explanation process after the announcement of the Financial Statements after the audit.